Axonics® to Present at the SVB Leerink Global Healthcare Conference

IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference, Tuesday, February 25, at 3:30pm ET in New York City, and will be available for meetings with institutional investors.

To access the live webcast of the fireside chat, please visit the Events & Presentations page of the Investor Relations section of the Company’s website at ir.axonics.com. A replay of the webcast will be available shortly after the conclusion of the fireside chat and will be archived on the Company’s website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company’s website at www.axonics.com.

Contacts

Axonics’ Contact

Axonics Modulation Technologies, Inc.

Dan Dearen, +1-949-396-6320

President & Chief Financial Officer

ir@axonics.com

Investor & Media Contact
W2Opure

Matt Clawson, +1-949-370-8500

mclawson@w2ogroup.com

Staff

Recent Posts

PrimeBiome— How PrimeBiome Gummies Boost Glowing Skin With Bacillus Coagulans & Babchi

Clinically-Inspired Supplement PrimeBiome Gains Momentum in 2025 as Consumers Report Radiant Skin, Improved Gut Health,…

2 days ago

Lipozem Reviews (BUYER ALERT!) Is It Legit And Safe To Use? Consumer Report On Reddit Breaks It Down!

MIAMI, April 12, 2025 (GLOBE NEWSWIRE) -- The Lipozem weight loss supplement has been garnering…

2 days ago

Kane Biotech Announces New Agreement with Outside the Box Capital Inc.

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG,…

2 days ago

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2024 Financial Results on April 14, 2025

FREDERICK, Md., April 11, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ),…

2 days ago

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ:…

2 days ago

Ontario’s Measles Outbreak Requires Much More Visible & Effective Public Health Response

TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- The Ontario Health Coalition is raising concerns about…

2 days ago